Publications

Durairaj C, Ruiz-Garcia A, Gauthier ER, Huang X, Lu DR, Hoffman JT, Finn RS, Joy AA, Ettl J, Rugo HS, Zheng J, Wilner KD, Wang DD. Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer. Anti-cancer drugs. 2018. PMID: 29360661

Fadelu T, Zhang S, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson AB, Atienza DM, Messino M, Kindler HL, Venook A, Ogino S, Ng K, Wu K, Willett W, Giovannucci E, Meyerhardt J, Bao Y, Fuchs CS. Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018. PMID: 29489429

Loibl S, O'Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, Huober J, Golshan M, von Minckwitz G, Maag D, Sullivan D, Wolmark N, McIntyre K, Ponce Lorenzo JJ, Metzger Filho O, Rastogi P, Symmans WF, Liu X, Geyer CE. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. The Lancet. Oncology. 2018. PMID: 29501363

Wei XX, Siegel AP, Aggarwal R, Lin AM, Friedlander TW, Fong L, Kim W, Louttit M, Chang E, Zhang L, Ryan CJ. A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer. The oncologist. 2018. PMID: 29487219

Hala T Borno, Joseph P. McGuire, Ann C. Griffin, Charles J. Ryan, Celia Kaplan, Eric Jay Small. Journal of Clinical Oncology Minority Equity and Recruitment Into Trials program: Self-assessment of disease-specific cancer clinical trial recruitment patterns at a comprehensive cancer center.. 2018. PMID:

Koshkin VS, Barata PC, Rybicki LA, Zahoor H, Almassi N, Redden AM, Fergany AF, Kaouk J, Haber GP, Stephenson AJ, Ornstein MC, Gilligan T, Garcia JA, Rini BI, Grivas P. Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function. Clinical genitourinary cancer. 2018. PMID: 29576445

Forester CM, Zhao Q, Phillips NJ, Urisman A, Chalkley RJ, Oses-Prieto JA, Zhang L, Ruggero D, Burlingame AL. Revealing nascent proteomics in signaling pathways and cell differentiation. Proceedings of the National Academy of Sciences of the United States of America. 2018. PMID: 29467287

Hala Borno, Janet E. Cowan, Shoujun Zhao, Peter Carroll, Charles J. Ryan. CaPSURE update: Examining primary treatment and survival among men with prostate cancer and bony metastatic disease. Journal of Clinical Oncology. 2018. PMID:

Hala Borno, Joseph P. McGuire, Ann C. Griffin, Charles J. Ryan, Celia Kaplan, Eric Jay Small. Minority Equity and Recruitment Into Trials program: Self-assessment of disease-specific cancer clinical trial recruitment patterns at a comprehensive cancer center. Journal of Clinical Oncology. 2018. PMID:

Cheng ML, Iyer G. Novel biomarkers in bladder cancer. Urologic oncology. 2018. PMID: 29472156

Aggarwal R. Defining the Prognostic and Predictive Impact of Germline DNA Repair Mutations in Patients with Metastatic Castration-resistant Prostate Cancer. European urology. 2018. PMID: 29458985

Gonzalez VD, Samusik N, Chen TJ, Savig ES, Aghaeepour N, Quigley DA, Huang YW, Giangarrà V, Borowsky AD, Hubbard NE, Chen SY, Han G, Ashworth A, Kipps TJ, Berek JS, Nolan GP, Fantl WJ. Commonly Occurring Cell Subsets in High-Grade Serous Ovarian Tumors Identified by Single-Cell Mass Cytometry. Cell reports. 2018. PMID: 29444438

Chambers MS, Rugo HS, Litton JK, Meiller TF. Stomatitis associated with mammalian target of rapamycin inhibition: A review of pathogenesis, prevention, treatment, and clinical implications for oral practice in metastatic breast cancer. Journal of the American Dental Association (1939). 2018. PMID: 29439772

Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ, SPARTAN Investigators. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. The New England journal of medicine. 2018. PMID: 29420164

Neisler J, Reitzel LR, Garey L, Kenzdor DE, Hébert ET, Vijayaraghavan M, Businelle MS. Concurrent nicotine and tobacco product use among homeless smokers and associations with cigarette dependence and other factors related to quitting. Drug and alcohol dependence. 2018. PMID: 29448145

Beel AJ, Demos DS, Chung A, Liao C, Lui NS. Ground-glass opacity heralding invasive lung adenocarcinoma with prodromal dermatomyositis: a case report. Journal of cardiothoracic surgery. 2018. PMID: 29415746

Juric D, Rodon J, Tabernero J, Janku F, Burris HA, Schellens JHM, Middleton MR, Berlin J, Schuler M, Gil-Martin M, Rugo HS, Seggewiss-Bernhardt R, Huang A, Bootle D, Demanse D, Blumenstein L, Coughlin C, Quadt C, Baselga J. Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018. PMID: 29401002

Karachaliou N, Chaib I, Cardona AF, Berenguer J, Bracht JWP, Yang J, Cai X, Wang Z, Hu C, Drozdowskyj A, Servat CC, Servat JC, Ito M, Attili I, Aldeguer E, Capitan AG, Rodriguez J, Rojas L, Viteri S, Molina-Vila MA, Ou SI, Okada M, Mok TS, Bivona TG, Ono M, Cui J, Ramón Y Cajal S, Frias A, Cao P, Rosell R. Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis. EBioMedicine. 2018. PMID: 29433983

Corcoran RB, André T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Middleton G, Muro K, Gordon MS, Tabernero J, Yaeger R, O'Dwyer PJ, Humblet Y, De Vos F, Jung AS, Brase JC, Jaeger S, Bettinger S, Mookerjee B, Rangwala F, Van Cutsem E. Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer. Cancer discovery. 2018. PMID: 29431699

Horwitz SM, Ansell SM, Ai WZ, Barnes J, Barta SK, Choi M, Clemens MW, Dogan A, Greer JP, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Kim YH, Lunning MA, Mehta A, Mehta-Shah N, Oki Y, Olsen EA, Pro B, Rajguru SA, Shanbhag S, Shustov A, Sokol L, Torka P, Wilcox R, William B, Zain J, Dwyer MA, Sundar H. NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018. Journal of the National Comprehensive Cancer Network : JNCCN. 2018. PMID: 29439173